Day One Shares Surge After $2.5B Servier Deal

Group 1 - Day One Biopharmaceuticals, Inc. is being acquired by Servier for $21.50 per share in cash, totaling an equity value of approximately $2.5 billion [2][3] - The acquisition price represents a premium of about 68% over Day One's closing price on March 5 and approximately 86% over the one-month volume weighted average price as of March 5 [2] - The acquisition aims to expand Servier's oncology pipeline and strengthen its position in rare oncology, particularly in pediatric low-grade glioma [3] Group 2 - Following the acquisition announcement, Day One shares are trading 65.18% higher at $21.11 [4] - The transaction is expected to close in the second quarter of 2026, pending customary closing conditions including shareholder tender requirements and U.S. antitrust clearance [3]